Phase 1/2 Trial for an Experimental Phenylketonuria Gene Therapy Has Begun Enrollment

According to a story from globenewswire.com, the genetic medicines company Homology Medicines, Inc. has recently announced that it has opened enrollment for its phase 1/2 clinical trial. This clinical trial…

Continue Reading Phase 1/2 Trial for an Experimental Phenylketonuria Gene Therapy Has Begun Enrollment
ICYMI: First Patient is Dosed in Phase 2 Friedreich’s Ataxia Trial
HeungSoon / Pixabay

ICYMI: First Patient is Dosed in Phase 2 Friedreich’s Ataxia Trial

According to a story from Ysios Capital, the biotechnology company Minoryx Therapeutics recently announced that the first patient has been dosed in the company's phase 2 clinical trial. This trial…

Continue Reading ICYMI: First Patient is Dosed in Phase 2 Friedreich’s Ataxia Trial
Immunotherapy Elicits Positive Response in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients
source: pixabay.com

Immunotherapy Elicits Positive Response in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients

According to a story from mdmag.com, a recent study that was presented at the 2019 meeting of the American Society of Clinical Oncology has demonstrated the potential of a two…

Continue Reading Immunotherapy Elicits Positive Response in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients
Potential Treatment for Neurofibromatosis Type 1 Earns Fast Track Designation
Free-Photos / Pixabay

Potential Treatment for Neurofibromatosis Type 1 Earns Fast Track Designation

According to a story from Acrofan, the biopharmaceutical company SpringWorks Therapeutics, Inc. has recently announced the that company's experimental product candidate PD-0325901 has earned Fast Track designation from the US…

Continue Reading Potential Treatment for Neurofibromatosis Type 1 Earns Fast Track Designation

Novel Finding Could Lead to the Development of a “Resistance-Proof” Antiviral Drug

A recent study published in PLOS Biology has shown a promising new vulnerability within human viruses which could lead to the development of a new antiviral drug. This study was…

Continue Reading Novel Finding Could Lead to the Development of a “Resistance-Proof” Antiviral Drug

ICYMI: Gene Therapy That Could Make β-Thalassemia Patients Transfusion Independent Receives Marketing Authorization in EU

Transfusion-Dependent β-Thalassemia (TDT) Transfusion-dependent β-thalassemia (TDT) is a rare disease that is caused by a mutated β-globin gene. This mutation causes the amount of hemoglobin in the body to be…

Continue Reading ICYMI: Gene Therapy That Could Make β-Thalassemia Patients Transfusion Independent Receives Marketing Authorization in EU
Orphazyme Preps to File European Marketing Application for Experimental Niemann-Pick disease Type C Drug
stevepb / Pixabay

Orphazyme Preps to File European Marketing Application for Experimental Niemann-Pick disease Type C Drug

According to a press release from Danish biopharmaceutical company Orphazyme, the Company intents to proceed with a marketing authorisation application (MAA) for its experimental Niemann-Pick disease type C treatment arimoclomol.…

Continue Reading Orphazyme Preps to File European Marketing Application for Experimental Niemann-Pick disease Type C Drug

Extremely Positive Results Announced from Interim Analysis of Phase 2 Clinical Trial for Hemochromatosis

Hereditary Hemochromatosis Hereditary hemochromatosis (HH) is a rare disease caused by hepcidin deficiency or hepcidin insensitivity. Hepcidin naturally regulates iron absorption/distribution in the body. Without hepcidin, HH patients suffer from…

Continue Reading Extremely Positive Results Announced from Interim Analysis of Phase 2 Clinical Trial for Hemochromatosis

The FDA is Reversing Course on Unapproved Products Sold by Stem Cell Manufacturers

  The FDA’s “untitled letter” to R3 Stem Cell (R3), based in Scottsdale Arizona, cautioned R3 that the product they are marketing is considered a drug. It must, therefore, be…

Continue Reading The FDA is Reversing Course on Unapproved Products Sold by Stem Cell Manufacturers
Experimental Beta Thalassemia Drug Gains Temporary Short-Term Approval in Europe
Capri23auto / Pixabay

Experimental Beta Thalassemia Drug Gains Temporary Short-Term Approval in Europe

According to a publication from BNN Bloomberg, regulatory authorities in the European Commission recently granted conditional marketing authorization (CMA) to Zynteglo. Zynteglo is a gene therapy designed to treat beta…

Continue Reading Experimental Beta Thalassemia Drug Gains Temporary Short-Term Approval in Europe

Very First Patient Dosed with Investigational Therapy for Friedreich’s Ataxia in Phase 2 Clinical Trial

Friedreich's Ataxia Friedreich's ataxia (FRDA) is a rare disease which is caused by a frataxin deficiency. This deficiency results in the degeneration of nerves within the spinal cord. This nerve…

Continue Reading Very First Patient Dosed with Investigational Therapy for Friedreich’s Ataxia in Phase 2 Clinical Trial